CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 1,125,000 shares at a public offering price of $10.75 per share. As a result, the company will issue a total of 8,625,000 shares in the offering and will receive aggregate net proceeds, after underwriting discounts and commissions and other estimated offering expenses, of approximately $86.9 million. The offering is expected to close on February 21, 2012, subject to the satisfaction of customary closing conditions.
